A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00128284 |
Recruitment Status :
Completed
First Posted : August 9, 2005
Last Update Posted : May 22, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Gastrointestinal Diseases Stomach Diseases Gastroparesis |
Gastric emptying scintigraphy is considered the gold standard for evaluating gastric emptying and is widely available. Accurate characterization of gastric emptying may guide medical and surgical treatment choices. In addition, these techniques may allow for monitoring of therapeutic results for follow-up patient management.
The SmartPill GI Monitoring System offers an alternative non-invasive method for characterizing disorders of the stomach. The system consists of an ingestible capsule that houses sensors for pH, temperature, and pressure, a receiver for receiving and storing signals from the capsule, and software for displaying data on a personal computer. The capsule samples at regular intervals and transmits the sensed pH, pressure, and temperature data to a portable receiver worn by the subject. After test completion, the recorded data is downloaded to a personal computer for subsequent evaluation.
Study Type : | Observational |
Actual Enrollment : | 148 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time |
Study Start Date : | February 2005 |
Actual Primary Completion Date : | October 2005 |
Actual Study Completion Date : | October 2005 |

Group/Cohort |
---|
Normal
healthy adult subjects with no history or current gastrointestinal disorders or conditions
|
Gastroparesis
Subjects with documented gastroparesis
|
- To demonstrate the correlation between the gastric residence time as determined by SmartPill GI Monitoring System and the gastric emptying time of a radiolabeled meal in both healthy subjects and patients with documented gastroparesis. [ Time Frame: 30 minute intervals up to 6 hours ]
- To demonstrate that the gastric residence time as determined by SmartPill GI Monitoring System can discriminate between healthy human subjects and patients with gastroparesis [ Time Frame: Continuous time measure until capsule elimination ]
- To characterize pressure patterns within the antrum and duodenum in healthy subjects and patients with documented gastroparesis [ Time Frame: Continuous time measure until capsule elimination ]
- To characterize total GI transit time in healthy subjects [ Time Frame: Continuous tume measure until capsule elimination ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Inclusion Criteria For Healthy Subjects:
- Healthy males and females between ages 18-65 years of age with no gastrointestinal disease as screened by the GI Disease Screening Questionnaire
- Average bowel movement frequency of at least one bowel movement within 48 hours
- Subjects with high probability for compliance and completion of the study
Inclusion Criteria For Subjects with Gastroparesis:
- Abnormal gastric emptying as defined by local standards and documented by nuclear medicine scintigraphy performed within the last two years.
- Males and females between ages 18-65 years of age.
- Average bowel movement frequency of at least one bowel movement within 72 hours
- Subjects with high probability for compliance and completion of the study
- Upper endoscopy or upper GI within last 3 years showing no evidence of gastric bezoar, stricture, or peptic ulcer.
Exclusion Criteria:
Exclusion Criteria For Healthy Subjects:
- Prior GI surgery
- Surgery within the past 3 months
- Diverticulitis
- Tobacco use within eight hours prior to capsule ingestion and during the 8 hour monitoring time.
- Alcohol use within 24 hours prior to capsule ingestion and throughout the entire monitoring period (up to 72 hours).
- Body mass index (BMI) > 35
- Allergies to components of the test meal including eggs, bread, and jam.
- Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test)
- Cardiovascular, endocrine, renal, or other chronic disease likely to affect motility.
Exclusion Criteria For Subjects with Gastroparesis:
- History of gastric bezoar
- Severe dysphagia to solid food and pills
- Severe vomiting more than 1 time per day
- Diverticulitis
- Severe daily abdominal pain requiring medications for relief
- Severe weight loss, greater than 10 lbs over the preceding 2 months.
- Uncontrolled diabetes with a hemoglobin A1C greater than 10.
- Excessively delayed gastric emptying time: more than 90% of a standard egg meal retained after 2 hours.
- Previous gastro-esophageal surgery including vagotomy, fundoplication, gastric bypass, ulcer surgery.
- Prior GI surgery except for uncomplicated appendectomy and laparoscopic cholecystectomy
- Surgery within the past 3 months
- Tobacco use within eight hours prior to capsule ingestion and during the 8 hour monitoring time.
- Alcohol use within 24 hours prior to capsule ingestion and throughout the entire monitoring period (up to 72 hours).
- BMI > 35
- Allergies to components of the test meal including eggs, bread, and jam
- Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00128284
United States, Kansas | |
Division of Gastroenterology and Hepatology at KUMC | |
Kansas City, Kansas, United States, 66160 | |
United States, Kentucky | |
University of Louisville Medical Center | |
Louisville, Kentucky, United States, 40292 | |
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
United States, Michigan | |
University of Michigan Medical Center | |
Ann Arbor, Michigan, United States, 48109 | |
United States, New York | |
VA Medical Center | |
Buffalo, New York, United States, 14215 | |
United States, North Carolina | |
Wake Forest University Baptist Medical Center | |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Pennsylvania | |
Temple University Medical Center | |
Philadelphia, Pennsylvania, United States, 19140 |
Study Director: | Jack Semler, PhD | SmartPill Corporation | |
Principal Investigator: | Braden Kuo, MD | Massachusetts General Hospital |
Responsible Party: | John R. Semler/Chief Technology Officer, The SmartPill Corporation |
ClinicalTrials.gov Identifier: | NCT00128284 |
Other Study ID Numbers: |
102204 NYSTAR C020118 NIH DK069614 |
First Posted: | August 9, 2005 Key Record Dates |
Last Update Posted: | May 22, 2008 |
Last Verified: | May 2008 |
gastroparesis Digestive Gastrointestinal Stomach Motility |
Non-Invasive Capsule GI Device Digestive System Diseases |
Gastroparesis Gastrointestinal Diseases Digestive System Diseases |
Stomach Diseases Paralysis Neurologic Manifestations |